{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:20:09Z","timestamp":1787509209227,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 21K16022"],"award-info":[{"award-number":["JP 21K16022"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2024.01.012","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:54:33Z","timestamp":1706198073000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7622-8494","authenticated-orcid":false,"given":"Ryuki","family":"Chatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-1321","authenticated-orcid":false,"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-739X","authenticated-orcid":false,"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-5975","authenticated-orcid":false,"given":"Kazuhisa","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Mushiake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-3736","authenticated-orcid":false,"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-4899","authenticated-orcid":false,"given":"Moriaki","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-5642","authenticated-orcid":false,"given":"Shuhei","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-4076","authenticated-orcid":false,"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.01.012_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejim.2024.01.012_bib0002","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/cas.12525","article-title":"Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data","volume":"105","author":"Ito","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejim.2024.01.012_bib0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.01.012_bib0004","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0005","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2024.01.012_bib0006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.01.012_bib0007","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0008","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2024.01.012_bib0009","first-page":"4229","article-title":"ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J, Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ejim.2024.01.012_bib0010","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world\u2014from the command VTE registry","volume":"82","author":"Yamashita","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.01.012_bib0011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2023.08.007","article-title":"Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants","volume":"118","author":"Kaneda","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0012","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world \u2013 from the command VTE registry","volume":"83","author":"Sakamoto","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.01.012_bib0013","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0014","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.01.012_bib0015","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.01.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.01.012_bib0017","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.012_bib0018","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.01.012_bib0019","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ejim.2024.01.012_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejim.2024.01.012_bib0021","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.amjmed.2017.11.042","article-title":"Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism","volume":"131","author":"Chai-Adisaksopha","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.01.012_bib0023","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"Sabatino","year":"2020","journal-title":"JACC Cardiooncol"},{"key":"10.1016\/j.ejim.2024.01.012_bib0024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3400\/avd.oa.21-00022","article-title":"Anticoagulant therapy for cancer-associated venous thromboembolism after cancer remission","volume":"14","author":"Hara","year":"2021","journal-title":"Ann Vasc Dis"},{"key":"10.1016\/j.ejim.2024.01.012_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0026","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0027","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0028","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2024.01.012_bib0029","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.thromres.2014.06.020","article-title":"Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"134","author":"G\u00f3mez-Outes","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.01.012_bib0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2020.09.008","article-title":"Patterns of anticoagulation use in patients with cancer with atrial fibrillation and\/or atrial flutter","volume":"2","author":"Fradley","year":"2020","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.ejim.2024.01.012_bib0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jaccao.2022.07.004","article-title":"Outcomes by class of anticoagulant use for nonvalvular atrial fibrillation in patients with active cancer","volume":"4","author":"Potter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.01.012_bib0032","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.012_bib0033","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/eurheartj\/ehz367","article-title":"Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor Rivaroxaban: an international multicentre single-arm clinical trial","volume":"41","author":"Barco","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.012_bib0034","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.chest.2019.08.2206","article-title":"Usefulness of simplified pulmonary embolism severity index score for identification of patients with low-risk pulmonary embolism and active cancer: from the COMMAND VTE Registry","volume":"157","author":"Yamashita","year":"2020","journal-title":"Chest"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T14:59:56Z","timestamp":1715093996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":34,"alternative-id":["S0953620524000219"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}